Bcr-Abl
Bcr-Abl inhibitors are targeted therapies that inhibit the Bcr-Abl fusion protein, which is formed due to the Philadelphia chromosome translocation and is a driver of chronic myeloid leukemia (CML). This protein also influences angiogenesis, contributing to tumor progression. Bcr-Abl inhibitors are crucial in the treatment of CML and are being explored for their potential in inhibiting angiogenesis in various cancers. At CymitQuimica, we provide high-quality Bcr-Abl inhibitors to support your research in cancer biology, angiogenesis, and targeted therapy.
Found 119 products for "Bcr-Abl".
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
SNIPER(ABL)-024
CAS:SNIPER(ABL)-024, a compound that conjugates GNF5 (ABL inhibitor) to an LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels,Formula:C52H61F3N8O9SPurity:98%Color and Shape:SolidMolecular weight:1031.15SIAIS100
SIAIS100, a potent BCR-ABL PROTAC degrader, demonstrates a DC50 value of 2.7 nM, highlighting its efficacy.Formula:C44H50ClF2N9O5SColor and Shape:SolidMolecular weight:890.44BCR-ABL-IN-9
BCR-ABL-IN-9 (Compound B1) is an inhibitor of BCR-ABL that achieves sustained suppression through the formation of stable covalent bonds with the ABL kinase. It effectively inhibits the activity of ABL kinase (IC50 = 1.2 nM) and possesses anticancer activity.Formula:C22H20N4O3Color and Shape:SolidMolecular weight:388.42TG-100435
CAS:TG-100435 is a novel multi-target oral protein tyrosine kinase inhibitor. The metabolic flux of TG100435 is entirely inhibited by methimazole and ketoconazole. In human liver microsomes or recombinant P450, the formation of TG100435 increases with the activity of cytochrome P450 reductase, suggesting that cytochrome P450 reductase may be involved.Formula:C26H25Cl2N5OColor and Shape:SolidMolecular weight:494.42HG-7-85-01-NH2
CAS:HG-7-85-01-NH2, as the ligand for SNIPER(ABL)-033, effectively induces the reduction of BCR-ABL protein. This is achieved through SNIPER(ABL)-033, which connects HG-7-85-01 (an ABL inhibitor) to an LCL161 derivative (an IAP ligand) using a linker, demonstrating a DC50 value of 0.3 μM [1].Formula:C27H27F3N6OSColor and Shape:SolidMolecular weight:540.6c-ABL-IN-1
CAS:C-ABL-IN-1 is a new and specific inhibitor of the c-Abl protein, which effectively prevents the progression of neurodegeneration observed in Parkinson's diseaseFormula:C17H16Cl2FN3OSColor and Shape:SolidMolecular weight:400.29Asciminib hydrochloride
CAS:Asciminib hydrochloride is a STAMP inhibitor targeting the ABL myristoyl pocket, applied in Ph+ CML research for selective oncogenic signaling modulation.Formula:C20H19Cl2F2N5O3Purity:99.91%Color and Shape:White SolidMolecular weight:486.3Ref: TM-T63226
1mg57.00€5mg130.00€1mL*10mM (DMSO)138.00€10mg177.00€25mg289.00€50mg409.00€100mg620.00€Agerafenib
CAS:Agerafenib (CEP32496) is a highly potent inhibitor of BRAF.Formula:C24H22F3N5O5Purity:95.78% - 99.23%Color and Shape:White SolidMolecular weight:517.46Ref: TM-T2070
1mg39.00€1mL*10mM (DMSO)90.00€5mg93.00€10mg124.00€25mg219.00€50mg358.00€100mg530.00€200mg757.00€GNF-7
CAS:GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 nM, respectively.Formula:C28H24F3N7O2Purity:97.05% - 99.7%Color and Shape:SolidMolecular weight:547.53Degrasyn
CAS:Degrasyn (WP1130) inhibits DUBs (USP5, UCH-L1, USP9x, USP14, UCH37) and Bcr/Abl without affecting the 20S proteasome.Formula:C19H18BrN3OPurity:98.32% - 99.98%Color and Shape:SolidMolecular weight:384.27Ref: TM-T6300
2mg39.00€5mg57.00€1mL*10mM (DMSO)63.00€10mg96.00€25mg178.00€50mg306.00€100mg477.00€200mg672.00€Nocodazole
CAS:Nocodazole: synthetic microtubule polymerization blocker, also impedes Abl with low IC50; binds to beta-tubulin.Formula:C14H11N3O3SPurity:98% - 99.91%Color and Shape:Yellow SolidMolecular weight:301.32Ref: TM-T2802
5mg34.00€1mL*10mM (DMSO)38.00€10mg52.00€25mg94.00€50mg165.00€100mg268.00€200mg399.00€500mg647.00€Rebastinib
CAS:DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC,Formula:C30H28FN7O3Purity:99.53% - 99.79%Color and Shape:SolidMolecular weight:553.59SGX-523
CAS:SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.Formula:C18H13N7SPurity:99% - >99.99%Color and Shape:SolidMolecular weight:359.41Ref: TM-T2293
1mg34.00€2mg46.00€5mg84.00€1mL*10mM (DMSO)87.00€10mg114.00€25mg219.00€50mg349.00€100mg557.00€200mg790.00€Ponatinib
CAS:Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectivelyFormula:C29H27F3N6OPurity:98% - 99.60%Color and Shape:SolidMolecular weight:532.56NVP-BAW2881
CAS:NVP-BAW2881 (BAW2881) is a potent and selective VEGFR inhibitor with activity to inhibit chronic and acute skin inflammation.Formula:C22H15F3N4O2Purity:98.19% - 99.97%Color and Shape:White SolidMolecular weight:424.38Ref: TM-T3641
1mg34.00€2mg48.00€1mL*10mM (DMSO)69.00€5mg71.00€10mg109.00€25mg200.00€50mg324.00€100mg470.00€500mg1,054.00€AT9283
CAS:AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).Formula:C19H23N7O2Purity:99.83% - 99.98%Color and Shape:White SolidMolecular weight:381.43Ref: TM-T3068
2mg39.00€5mg75.00€1mL*10mM (DMSO)84.00€10mg111.00€25mg231.00€50mg371.00€100mg595.00€200mg833.00€Multi-kinase inhibitor 1
CAS:Multi-kinase inhibitor 1 (Multi-kinase inhibitor I) is a Multi-kinase inhibitor.Formula:C20H17F3N4O3Purity:99.87%Color and Shape:SolidMolecular weight:418.37Ref: TM-T4191
1mg37.00€2mg52.00€5mg79.00€1mL*10mM (DMSO)87.00€10mg101.00€25mg177.00€50mg268.00€100mg385.00€Flumatinib
CAS:Flumatinib (HHGV678) is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.Formula:C29H29F3N8OPurity:99.39% - 99.95%Color and Shape:White SolidMolecular weight:562.59Ref: TM-T4320
1mg34.00€5mg63.00€10mg82.00€1mL*10mM (DMSO)82.00€25mg120.00€50mg155.00€100mg259.00€200mg388.00€500mg642.00€AG1024
CAS:AG1024 (Tyrphostin) suppresses IGF-1R autophosphorylation(IC50=7 μM), and is less potent for IR(IC50=57 μM).Formula:C14H13BrN2OPurity:98% - 99.37%Color and Shape:SolidMolecular weight:305.17Olverembatinib dimesylate
CAS:Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).Formula:C29H27F3N6O·2CH4O3SPurity:97.66% - >99.99%Color and Shape:SolidMolecular weight:724.77Ref: TM-T2429
1mg37.00€5mg79.00€10mg113.00€1mL*10mM (DMSO)114.00€25mg216.00€50mg289.00€100mg378.00€200mg552.00€
